Targeted NGS (Next-Generation Sequencing) is a powerful tool that has revolutionized cancer research. At Genet, we offer a range of targeted NGS services to support clinical research in oncology.
Targeted NGS involves sequencing specific regions of the genome that are known to be relevant to cancer, such as genes involved in tumor formation, progression, and response to therapy. By analyzing these regions, we can identify genetic mutations and variations that may be contributing to cancer development, and gain a better understanding of the underlying mechanisms of the disease.
Our targeted NGS services for cancer research include:
- Tumor profiling: We sequence the DNA of tumor samples to identify genetic mutations and variations that may be driving cancer growth. This information can help clinicians select the most appropriate treatment options for individual patients.
- Liquid biopsy: We sequence circulating tumor DNA (ctDNA) in blood samples to monitor cancer progression and treatment response over time. Liquid biopsy is a non-invasive alternative to traditional tissue biopsy and can provide valuable information for personalized cancer care.
- Hereditary cancer testing: We sequence genes that are known to be associated with hereditary cancer syndromes, such as BRCA1 and BRCA2. Identifying inherited mutations can help individuals and their families take steps to reduce their risk of developing cancer.
- Companion diagnostics: We develop NGS-based tests to identify patients who are likely to respond to specific cancer therapies. This can help ensure that patients receive the most effective treatments and avoid unnecessary side effects.
At Genet, we use state-of-the-art NGS platforms and bioinformatics tools to provide accurate and reliable results. Our experienced team of scientists and clinicians can provide expert guidance on study design, sample preparation, data analysis, and interpretation.
